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Patients with chronic renal failure maintained on intermittent
hemodialysis have frequent infections and a suboptimal
response to vaccinations. Dendritic cells are potent
antigen-presenting cells essential for the initiation and
maintenance of innate and adaptive immunity. In this study
we used uremic sera from hemodialysis patients to measure
its impact on monocyte and monocyte-derived dendritic cell
function in vitro. Monocytes from healthy and uremic
subjects were isolated using immunomagnetic beads and
differentiated into dendritic cells in the presence of either
complete sera or sera from hemodialysis patients. Dendritic
cells from normal patients cultured in uremic sera had
decreased endocytosis and impaired maturation. These cells,
however, had enhanced IL-12p70 production and increased
allogeneic T-cell proliferation compared to cells of normal
subjects cultured in normal sera. Monocyte derived dendritic
cells of hemodialysis patients cultured in either normal or
uremic sera were functionally impaired for endocytosis and
maturation but had enhanced IL-12p70 production and
allogeneic T-cell proliferation only when cultured with uremic
sera. High concentrations of urea in normal sera inhibited all
aspects of normal dendritic cell function in vitro. Our study
suggests that hemodialysis regimes tailored to remove
uremic toxins more efficiently may improve immune
functions of these patients.
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Immune protection and surveillance against pathogens in
humans relies on a coordinated response of innate and
adaptive immune systems.1 Chronic renal failure (CRF)
patients have evidence of defects in both innate immunity
(e.g. reduced polymorphonuclear leukocytes chemotaxis,
phagocytosis, and bactericidal activity)2,3 and adaptive
immunity (reduced T-cell function) that contribute to
generalized immunodeficiency.4,5 Infection is a leading cause
of morbidity and mortality in CRF patients (including
hemodialysis (HD) and continuous ambulatory peritoneal
dialysis (CAPD) patients) that may be attributed to these
underlying immune defects in the innate system.6,7 In
addition, CRF patients display suboptimal responses to
therapeutic vaccinations (e.g. hepatitis B) characterized by
low antibody titers, and short duration of protection typical
of impairment of adaptive immunity.8,9 These deficiencies
observed in CRF patients may be attributed to defects in the
number and function of antigen-presenting cells, in parti-
cular dendritic cells (DC),10 but their role in the pathogenesis
of innate and adaptive immune dysfunction in CRF patients
has not been defined clearly.
DC are a group of rare, heterogenous population of
professional antigen-presenting cells that initiate primary
immune responses, and regulate both innate and adaptive
immunity.11–13 DC are critical in stimulating naı¨ve T-cell
responses to captured foreign antigens.14,15 Following antigen
capture and processing, DC undergo maturation and migrate
to secondary lymphoid tissues where they present processed
antigen/peptide coupled to major histocompatibility com-
plexes, which allow for selection and expansion of antigen-
specific CD4þ T-helper cells.
DC may be differentiated in vitro from monocyte
precursors and provide a model system whereby these
otherwise rare antigen-presenting cells may be generated in
sufficient numbers for studies.16 DC-based vaccination has
been utilized successfully in certain clinical conditions to
generate immunity to certain pathogens.17–19 Monocytes
cultured in the presence of granulocyte macrophage colony-
stimulating factor and interleukin (IL)-4 for 5 days
differentiate into immature monocyte-derived DC (MoDC)
characterized by low expression of major histocompatibility
complex class II molecules, costimulatory molecules (CD40,
CD80, and CD86), and the DC maturation marker, CD83.
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Bacterial lipopolysaccharide (LPS), tumor necrosis factor-a,
and CD40 ligand can be used for the induction of DC
maturation without cell proliferation.20,21
In a previous study, we established that circulating
myeloid DC precursors from HD patients displayed func-
tional impairment with reduced cell-surface costimulatory
molecule expression following maturational signals.22 We
hypothesized that the presence of uremic toxins in the serum
of HD patients are responsible for the observed impairment
in DC functions. In this study, we used MoDC system to
assess the impact of uremic sera from HD patients on
monocyte and MoDC functions.
RESULTS
Monocytes
HD patients have high levels of IL-12p70. The serum
concentration of bioactive IL-12p70 was significantly higher
in the sera of HD patients (52.8718.1 pg/ml), CAPD patients
(12.673.8 pg/ml), and CRF patients (49.675.5 pg/ml) when
compared to healthy controls and pooled human AB serum
(both below the level of detection; Mann–Whitney U-test
Po0.001).
Uremic medium inhibits normal monocyte function. To
determine the effect of uremic serum on monocyte function,
we studied normal monocytes cultured in uremic medium
(UM). LPS-stimulated normal monocytes cultured in UM
demonstrated reduced expression of costimulatory molecules
(CD40, CD80, and CD86) compared to normal monocytes in
complete medium (CM) (Figure 1a and Table 1). Consistent
with this observation, UM-cultured monocytes displayed
reduced allo-stimulatory capacity (Mann–Whitney U-test,
Po0.0001; Figure 1b) when compared to monocytes in CM.
The amount of IL-12p70 present in CM and UM was below
the level of detection and 13.573.2 pg/ml, respectively
(Mann–Whitney U-test, Po0.001). Monocytes cultured in
CM or UM produced no additional IL-12p70 in excess of
background amount of IL-12p70 in mediums (sera of 5 HD
patients used).
Uremic monocytes from HD patients are functionally abnor-
mal. Freshly isolated uremic monocytes from HD patients
exhibited reduced fluorescein isothiocyanate (FITC)-dextran
uptake compared to normal monocytes (representative of
three HD patients, mean fluorescent intensity (MFI) 9.272.3
and 25.475.2, respectively; Student’s t-test, P¼ 0.02).
Following LPS stimulation, uremic monocytes cultured in
CM, but not when cultured in autologous UM, upregulated
cell-surface expression of costimulatory molecules CD40,
CD80, and CD86, but not to the same extent of LPS-
stimulated normal monocytes cultured in CM (Figure S1 and
Table 1). Consistent with this observation, uremic monocytes
in CM showed greater allo-stimulatory capacity compared to
uremic monocytes cultured in autologous UM (Mann–Whit-
ney U-test, Po0.0001; Figure S2). Uremic monocytes
cultured in CM or autologous UM produced no detectable
levels of IL-12p70 in excess of background levels in mediums
(representative of three experiments).
Monocyte-derived dendritic cells
UM does not affect the differentiation of monocytes into MoDC
but inhibits MoDC functions. To determine the effects of
uremic serum on the differentiation of monocytes into
MoDC and MoDC function, we studied normal monocytes/
MoDC cultured in UM. Compared to normal immature
MoDC in CM, normal immature MoDC cultured in UM
exhibited reduced FITC-dextran uptake (sera of 10 separate
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Figure 1 | Uremic medium inhibits costimulatory molecule
expression and allo-stimulatory capacity of monocytes. (a)
Cell-surface expression of costimulatory molecules on LPS-stimulated
(10 ng/ml) normal monocytes of healthy blood donors cultured in
either CM or UM for 24 h. Flow cytometric analysis revealed reduced
cell-surface expression of costimulatory molecules (CD40, CD80, and
CD86) on monocytes cultured in UM compared to cells cultured in
CM (closed profiles). Open black profiles denote isotype controls.
Representative histograms are shown. MFI (mean7s.d.) below
histograms representative of results of eight experiments involving
the sera of eight separate HD patients (Mann–Whitney U-test,
*Po0.05). (b) Allogeneic T-cell proliferation in a monocytes/T cells
two-way MLR. LPS-stimulated (10 ng/ml) normal monocytes of
healthy blood donors cultured in CM for 24 h induced greater
allogeneic T-cell proliferation (measured as tritiated thymidine
incorporated cells) compared to normal monocytes cultured in UM
for 24 h (Mann–Whitney U-test, Po0.0001). Results representative of
four separate experiments.
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HD patients used, MFI 45.276.8 and 15.577.2, respectively;
Mann–Whitney U-test, Po0.05) and reduced cell-surface
expression of CD206 (sera of 10 separate HD patients used,
MFI 60.5710.2 and 8.272.5; Mann–Whitney U-test,
Po0.01). The differentiation of normal monocytes cultured
in CM or UM into MoDC was complete and unaffected by
the presence of uremic serum. LPS-stimulated MoDC derived
from normal monocytes cultured in UM demonstrated
reduced cell-surface expression of costimulatory (CD40,
CD80, and CD86) and maturation (CD83) markers (Figure 2a
and Table 2).
A greater proportion of normal LPS-stimulated MoDC
cultured in UM compared to CM were apoptotic and/or
necrotic (sera of three separate HD patients used; Student’s
t-test, Po0.05; Table 2). CD95 expression was similar in
normal LPS-stimulated MoDC cultured in UM and CM (sera
of 10 separate HD patients used, MFI 4.872.2 and 3.471.8,
respectively; P¼NS).
Normal LPS-stimulated MoDC cultured in UM produced
a greater amount of IL-12p70 (78.9724.4 pg/ml) when
compared to cells cultured in CM (32.2710.2 pg/ml, sera
of 10 separate HD patients used; Mann–Whitney U-test,
P¼ 0.01). The amount of IL-12p70 present in CM and UM
was below the level of detection and 9.572.1 pg/ml,
respectively (Mann–Whitney U-test, Po0.01). Normal LPS-
stimulated MoDC cultured in UM demonstrated enhanced
allo-stimulatory capacity compared to cells in CM (Mann–
Whitney U-test, P¼ 0.009; Figure 2b). In order to investigate
the impact of small MW uremic toxins on MoDC functions,
the effect of urea, a recognized small MW uremic toxin
present at increased concentrations in the uremic sera of HD
patients on normal MoDC functions was assessed.
High concentration of urea inhibits normal MoDC function. In-
creasing concentrations of urea were added to CM containing
normal monocytes in levels equivalent to CRF patients.
However, only normal monocytes cultured in CM supple-
mented with 40 mmol/l of urea inhibited monocyte differ-
entiation into immature MoDC and exhibited reduced
expression of costimulatory molecules and CD83 on LPS-
stimulated MoDC. Monocytes cultured in CM alone or CM
supplemented with lower concentrations of urea (5 and
20 mmol/l) displayed appropriate monocyte differentiation
into immature MoDC and subsequent maturation following
LPS stimulation (Figure 3a and Table 3). Normal immature
MoDC cultured in CM containing 40 mmol/l urea demons-
trated reduced FITC-dextran uptake (MFI 39.6715.2) and
expression of CD206 (MFI 8.873.2) when compared to
immature MoDC cultured in CM alone (MFI 68.5710.2 and
40.576.2, respectively, representative of six separate experi-
ments; Mann–Whitney U-test, Po0.05). Immature MoDC
cultured in CM containing lower concentrations of urea
exhibited similar endocytic capacity (FITC-dextran uptake)
and CD206 expression as cells cultured in CM alone
(representative of six experiments, data not shown).
A greater proportion of LPS-stimulated normal MoDC
cultured in CM and 40 mmol/l urea were apoptotic and/or
necrotic when compared to cells cultured in CM alone. LPS-
stimulated MoDC cultured in CM containing lower con-
centrations of urea had similar percentage of apoptotic and/
or necrotic cells as MoDC cultured in CM alone (representa-
tive of three experiments, P¼NS; Table 3). CD95 expression
on LPS-stimulated normal MoDC was not affected by the
presence of any concentrations of urea in CM (representative
of six experiments, data not shown).
Increasing concentrations of urea imparted a dose-
dependent inhibition in the ability of LPS-stimulated normal
MoDC to produce IL-12p70 detected by enzyme-linked
immunosorbent assay (ELISA). LPS-stimulated MoDC
cultured in CM alone produced 35.774.6 pg/ml of IL-
12p70, whereas MoDC cultured in CM containing 5 mmol/l
(28.476.9 pg/ml), 20 mmol/l (26.174.9 pg/ml), and
40 mmol/l (below the level of detection) of urea produced
less IL-12p70 (representative of eight separate experiments;
Kruskal–Wallis test, Po0.05). There was no detectable IL-
12p70 in CM7urea. However, only LPS-stimulated normal
MoDC cultured in CM and 40 mmol/l urea significantly
inhibited allogeneic T-cell proliferation compared to MoDC
cultured in the absence/lower concentrations of urea in CM
(Figure 3b; Kruskal–Wallis test, P¼ 0.1).
Uremic sera of CAPD and CRF patients also affect MoDC
function and survival. In order to investigate the impact of
uremia and dialysis modality on MoDC functions, the effect
of the sera of CAPD and CRF patients on normal MoDC
functions was assessed. Compared to normal immature
MoDC in CM, normal immature MoDC cultured in UM
containing either sera of CAPD and CRF patients demons-
trated similar capacity for FITC-dextran uptake (sera of
three separate CAPD and CRF patients used, MFI
113.2715.8, 145.6789.2, and 123.6710.5, respectively;
P¼NS). LPS-stimulated MoDC derived from normal
Table 1 | Costimulatory molecule expression of normal and uremic monocytes in complete and uremic media
Monocytes CD40 MFI (mean7s.d.)* CD80 MFI (mean7s.d.)* CD86 MFI (mean7s.d.)*
Normal monocytes in CM#,w 8.771.6 2.770.6 3.370.9
Normal monocytes in UM# 2.370.6 1.971.1 2.171.5
Uremic monocytes in CMw 3.371.1 1.970.5 2.270.7
Uremic monocytes in autologous UM 0.070.0 0.070.0 0.070.0
CM, complete medium; MFI, mean fluorescent intensity; s.d., standard deviation; UM, uremic medium.
*Po0.05 Kruskal–Wallis test.
wPo0.05 Student’s t-test (CD40 only).
#Po0.05 Mann–Whitney U-test (CD40 only).
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Figure 2 | Uremic medium inhibits costimulatory molecule expression on monocyte-derived DC but enhances their allo-stimulatory
capacity in MLR. (a) Cell-surface expression of CD14, costimulatory molecules, and CD83 on normal LPS-stimulated (10 ng/ml) MoDC of
healthy blood donors cultured for 48 h in either CM or UM. Flow cytometric analysis revealed reduced cell-surface expression of
costimulatory molecules (CD40, CD80, and CD86) and CD83 (maturation marker) on MoDC cultured in UM compared to cells cultured in
CM (closed profiles). There was negligible/absent cell-surface expression of CD14 demonstrated on both MoDC cultured in CM or UM
suggesting that all monocytes had differentiated into MoDC (closed profiles). Open black profiles denote isotype controls. Representative
histograms are shown. MFI (mean7s.d.) below histograms representative of results of 10 experiments involving the sera of 10 separate
HD patients (Mann–Whitney U-test *Po0.05). (b) Allogeneic T-cell proliferation in an MoDC/T cells two-way MLR. Normal LPS-stimulated
(10 ng/ml) MoDC of healthy blood donors cultured in UM for 48 h induced a greater proliferation of allogeneic T cells compared to
MoDC cultured in CM for 48 h (Mann–Whitney U-test, P¼ 0.009). Results representative of five separate experiments.
Table 2 | Costimulatory molecule expression and viability of normal and uremic monocyte-derived dendritic cells in complete
and uremic (sera of hemodialysis patients) mediums
MoDC
CD40 MFI
(mean7s.d.)*
CD80 MFI
(mean7s.d.)*
CD83 MFI
(mean7s.d.)*
CD86 MFI
(mean7s.d.)*
Apoptotic/necrotic cells
(% total cells)#
Normal MoDC in CMw,z 189.1718.9 12.174.5 6.672.3 20.176.5 41.1710.2
Normal MoDC in UMw 33.9710.2 7.273.2 4.171.2 7.972.3 82.4712.9
Uremic MoDC in CMz 7.973.2 0.470.3 0.270.1 0.570.3 —
Uremic MoDC in autologous UM 1.170.5 0.170.0 0.370.1 0.370.3 —
CM, complete medium; MFI, mean fluorescent intensity; MoDC, monocyte-derived dendritic cells; s.d., standard deviation; UM, uremic medium.
*Po0.05 Kruskal–Wallis test.
#Po0.05 Student’s t-test.
wPo0.05 Mann–Whitney U-test (except CD83).
zPo0.05 Mann–Whitney U-test.
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CD14 CD40* CD80* CD83
With urea 5 mmol/l
With urea 20 mmol/l
With urea 40 mmol/l
MFI 15.6±5.2MFI 147.2±33.8 MFI 7.8±2.1MFI 0.4±0.2
MFI 14.5±4.3 MFI 24.3±7.7MFI 160.2±44.5 MFI 8.6±3.2 MFI 0.3±0.2
MFI 15.3±4.9 MFI 149.3±41.2 MFI 20.1±11.1MFI 9.0±2.7MFI 0.2±0.1
MFI 7.3±3.3 MFI 11.1±4.4MFI 99.0±15.6 MFI 3.9±2.1MFI 0.6±0.3
CD86*
LPS-stimulated normal monocyte-derived DC in complete medium
MFI 26.9±8.7
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Figure 3 | The effect of urea on monocyte-derived DC costimulation molecule expression and allostimulatory capacity. (a) Cell-surface
expression of CD14, costimulatory molecules, and CD83 on normal LPS-stimulated (10 ng/ml) MoDC of healthy blood donors cultured in
CM with graded concentrations of urea for 48 h. Flow cytometric analysis revealed dose-dependent reduction in cell-surface expression of
costimulatory molecules (CD40, CD80, and CD86) and CD83 (maturation marker) on mature MoDC cultured in the presence of 40 mmol/l of
urea (iv) compared to cells cultured in the absence (i) or lower concentrations of urea (ii and iii). There was a slight increase in cell-surface
expression of CD14 demonstrated on MoDC cultured in the presence of the highest concentration of urea (40 mmol/l) suggesting that not all
monocytes in culture differentiated into DC (closed profiles). Open black profiles denote isotype controls. Representative histograms are
shown. MFI (mean7s.d.) below histograms representative of results of eight experiments involving the sera of eight separate HD patients
(Mann–Whitney U-test comparing panels (i) and (iv) *Po0.05 for CD40, CD80, and CD86 only). (b) The ability of MoDC cultured in the presence
of urea to stimulate allogeneic T-cell proliferation in an MLR. Normal LPS-stimulated (10 ng/ml) MoDC of healthy blood donors cultured for 48 h
in CM without urea or with 5 or 20 mmol/l of urea promoted a similar amount of T-cell proliferation. MoDC cultured in the presence of
40 mmol/l induced less allogeneic T-cell proliferation compared to MoDC cultured in the absence or lower concentrations of urea
(Kruskal–Wallis test, P¼NS). Result representative of three separate experiments.
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monocytes cultured in UM (containing either sera of CAPD
and CRF patients) demonstrated slightly reduced cell-surface
expression of CD80 and CD86, but not CD40 and CD83. The
differentiation of MoDC from monocytes was not affected by
the presence of uremic serum in cell culture (Figure S3 and
Table 4).
A greater proportion of normal LPS-stimulated MoDC
cultured in UM compared to CM were apoptotic and/or
necrotic (sera of three separate CAPD and CRF patients used,
P¼NS; Table 4). Normal LPS-stimulated MoDC cultured in
UM produced a greater amount of IL-12p70 (12.574.7 pg/ml
in UM containing sera of CAPD patients, and 155.57
25.9 pg/ml in UM containing sera of CRF patients) when
compared to cells cultured in CM (undetectable; Kruskal–-
Wallis test, Po0.01). The amount of IL-12p70 present in CM
and UM was both below the level of detection.
Uremic MoDC of HD patients are functionally abnormal. Ure-
mic monocytes from HD patients cultured in either CM
or autologous UM were capable of differentiating into
MoDC though there was a marginal increase in the number
of undifferentiated monocytes (Figure 4a). Compared to
normal immature MoDC cultured in CM, uremic immature
MoDC cultured in CM and autologous UM exhibited
reduced FITC-dextran uptake (50.876.7, 0.170.1, and
0.270.1, respectively, representative of three HD patients;
Kruskal–Wallis test, Po0.01) and reduced expression of
CD206 (108.5715.8, 0.370.2, and 0.370.1, respectively,
representative of three HD patients; Kruskal–Wallis test,
Po0.0001). Uremic LPS-stimulated MoDC cultured in CM
or autologous UM demonstrated reduced expression of
costimulatory molecules and CD83 compared to normal
MoDC cultured in CM (Figure 4a and Table 2).
LPS-stimulated uremic MoDC cultured in autologous UM
produced greater amount of IL-12p70 (34.2710.2 pg/ml)
than uremic MoDC cultured in CM (below the level of
detection, representative of three HD patients; Student’s
t-test, Po0.01). The amount of IL-12p70 present in CM and
UM was below the level of detection and 11.375.1 pg/ml,
respectively (Student’s t-test, Po0.01). As demonstrated with
normal MoDC cultured in UM, uremic MoDC cultured in
autologous UM exhibited greater allo-stimulatory capacity
than uremic MoDC cultured in CM (Kruskal–Wallis test,
P¼ 0.001; Figure 4b).
DISCUSSION
In this study, we demonstrated that uremic sera from HD
patients inhibited normal monocytes and MoDC function.
We established that the presence of uremic serum in cell
culture prevented the upregulation of costimulatory molecule
expression on monocytes (including CD40, CD80, and
CD86) following LPS stimulation resulting in reduced allo-
stimulatory capacity of monocytes in vitro. However, the
presence of uremic serum did not considerably affect the
differentiation of monocytes into MoDC in vitro but did
affect the function of immature and mature normal MoDC
post-differentiation. Immature MoDC generated in the
presence of uremic serum displayed suboptimal capacity for
endocytosis via macrophage mannose receptor pathway that
may directly reflect a reduction of CD206 expression on the
cell surface of these immature MoDC. Furthermore, the
presence of uremic serum inhibited the maturation of MoDC
demonstrated by lower expression of CD83 and costimula-
tory molecule expression despite LPS stimulation. However,
despite the lack of phenotypic maturation displayed by
Table 3 | Costimulatory molecule expression and viability of normal monocyte-derived dendritic cells in complete and uremic
(sera of peritoneal dialysis and chronic renal failure patients) mediums
MoDC
CD40 MFI
(mean7s.d.)
CD80 MFI
(mean7s.d.)
CD83 MFI
(mean7s.d.)
CD86 MFI
(mean7s.d.)*
Apoptotic/necrotic cells
(% total cells)
Normal MoDC in CM 104.2754.3 7.573.6 3.772.8 23.174.3 36.4712.2
Normal MoDC in UM (PD) 111.5724.6 3.272.6 0.870.5 11.174.7 54.5715.2
Normal MoDC in UM (CRF) 110.2764.3 4.372.7 1.470.9 15.277.2 50.1723.2
CM, complete medium; MFI, mean fluorescent intensity; MoDC, monocyte-derived dendritic cells; s.d., standard deviation; UM (CRF), uremic medium containing sera of
chronic renal failure patients; UM (PD), uremic medium containing sera of peritoneal dialysis patients.
*Po0.05 Kruskal–Wallis test.
Table 4 | Costimulatory molecule expression and viability of normal monocyte-derived dendritic cells in complete
medium7urea solution
MoDC
CD40 MFI
(mean7s.d.)
CD80 MFI
(mean7s.d.)
CD83 MFI
(mean7s.d.)
CD86 MFI
(mean7s.d.)
Apoptotic/necrotic cells
(% total cells)
Normal MoDC in CM* 147.2733.8 15.675.2 7.872.1 26.978.7 38.5710.5
Normal MoDC in CM+urea 5 mmol/l 160.2744.5 14.574.3 8.673.2 24.377.7 42.9712.2
Normal MoDC in CM+urea 20 mmol/l 149.3741.2 15.374.9 9.072.7 20.1711.1 40.8715.5
Normal MoDC in CM+urea 40 mmol/l* 99.0715.6 7.373.3 3.972.1 11.174.4 56.6720.2
CM, complete medium; MFI, mean fluorescent intensity; MoDC, monocyte-derived dendritic cells.
*Po0.05 Mann–Whitney U-test (except CD83).
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LPS-stimulated MoDC cultured in UM, their allo-stimula-
tory capacity and ability to secrete IL-12p70 were para-
doxically enhanced. A likely explanation for this unexpected
finding is the presence of IL-12p70 in the uremic serum of
HD patients. IL-12 is a proinflammatory cytokine that is an
important regulator of Th1 response and is produced
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Figure 4 | The effect of uremic serum on costimulatory molecule expression and allo-stimulatory capacity of uremic monocyte-derived
DC. (a) Cell-surface expression of CD14, costimulatory molecules, and CD83 on LPS-stimulated (10 ng/ml) uremic MoDC of HD patients
cultured in CM or autologous UM for 48 h. Flow cytometric analysis revealed absent or low cell-surface expression of costimulatory
molecules (CD40, CD80, and CD86) and CD83 (maturation marker) on MoDC cultured in either CM or UM. There was slight increase in
CD14 expression demonstrated on uremic MoDC cultured in either CM or UM suggesting that not all monocytes in culture had
differentiated into MoDC (closed profiles). Cell-surface expression of CD14, costimulatory molecules, and CD83 on normal LPS-stimulated
MoDC cultured in CM are shown for comparison. Open black profiles denote isotype controls. Representative histograms are shown. MFI
(mean7s.d.) below histograms representative of results of three HD patients (Kruskal–Wallis test, *Po0.05). (b) Allogeneic T-cell proliferation
in an MoDC/T cells two-way MLR. Uremic LPS-stimulated (10 ng/ml) MoDC of HD patients cultured in UM for 48 h induced a greater
proliferation of allogeneic T cells compared to uremic MoDC cultured in CM for 48 h (Kruskal–Wallis test, P¼ 0.001). The ability of normal
LPS-stimulated MoDC derived from healthy blood donors cultured in CM and UM to stimulate allogeneic T-cell proliferation is shown for
comparison. Result representative of three separate HD patients.
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predominantly by monocytes and DC.23 IL-12 is particularly
efficient in the induction of interferon-g by T cells, and both
IL-12 and interferon-g may provide a positive auto-
regulatory feedback to T cells and DC further promoting
interferon-g and IL-12 production, respectively.24 Higher
serum levels of IL-12 have been shown by others in the sera of
chronic HD patients, and the overproduction of IL-12 has
been associated with polarization of T-cell phenotype toward
Th1 responses in these patients.25,26 IL-12p70 present in
uremic serum may stimulate MoDC via IL-12 receptor to
enhance production of IL-12p70, which in turn augments
T-cell activation and proliferation manifesting as enhanced
by allo-stimulatory capacity of MoDC in the MoDC/T cell-
mixed lymphocyte reaction (MLR) in our study. In addition,
monocytes27 and T cells28 from uremic HD patients have also
been demonstrated to undergo accelerated apoptosis. Con-
sistent with these observations, our study established that
uremic serum induces greater MoDC apoptosis and necrosis
(and hence increased release of inflammatory mediators) that
may directly result in enhanced T-cell proliferation induced
by UM-cultured MoDC, further contributing to the immune
dysfunction of HD patients. Unlike MoDC, LPS-stimulated
monocytes cultured in either CM or UM did not produce
IL-12 and may explain why MoDC but not monocytes
cultured in UM exhibited enhanced allo-stimulatory capacity.
The latter may perhaps reflect the lack of IL-12 receptor on
monocytes29 essential for positive auto-regulatory feedback
and subsequent experiments are ongoing in our laboratory to
determine the extent of IL-12 receptor expression on
monocytes and MoDC (including in response to uremic
serum) and whether the inhibition of IL-12 receptor on UM-
cultured MoDC could inhibit their enhanced allo-stimulatory
capacity and the ability to produce IL-12. Furthermore,
neutralizing IL-12 activity in culture medium using a
blocking monoclonal antibody may also help to distinguish
which of the two factors (i.e. IL-12 or cell apoptosis) is
predominantly responsible for the amplified allo-stimulatory
capacity of MoDC cultured in UM.
Both low and high MW uremic toxins contained within
the uremic serum or plasma of dialysis-dependent patients
have been implicated in the observed dysfunction of the
innate immune system including polymorphonuclear leuko-
cytes30,31 and mononuclear phagocytes resulting in reduced
chemotaxis and oxidative activity in response to phago-
cytosis.32,33 Polymorphonuclear leukocyte function has been
shown to improve in CRF patients following commencement
of peritoneal dialysis suggesting that these soluble uremic
toxins may be removed by dialysis.34 This study identified
that high concentrations of urea (40 mmol/l), a recognized
small MW uremic toxin, inhibits normal MoDC functions
including reduced endocytosis and expression of costimula-
tory molecules following LPS stimulation comparable to the
effects of uremic serum on these cells in vitro. Unlike UM-
cultured MoDC, the presence of high concentrations of urea
inhibited the ability of LPS-stimulated MoDC to produce IL-
12p70 and allogeneic T-cell proliferation consistent with their
reduced capacity for endocytosis or undergo maturation.
However, it is likely that larger MW uremic toxins are also
present within uremic serum contributing to the negative
effects of uremic serum on monocytes/MoDC functions as
the inhibitory effects exerted by urea on MoDC occurred
only at the highest concentration of urea (40 mmol/l) in
CM. Furthermore, the presence of vitamin D analogs
(e.g. calcitriol) and aspirin in uremic serum is likely to
contribute to the inhibitory effects of uremic serum on DC
functions.
To address whether uremia or the process of HD was
predominantly responsible for the inhibitory effect of uremic
sera of HD patients on MoDC function, the effects of uremic
sera of CRF and CAPD patients on MoDC function were
analyzed in vitro. MoDC generated in the presence of UM
containing either the sera of CAPD or CRF patients inhibited
the upregulation of certain costimulatory molecules (CD80
and CD86) and exhibited enhanced apoptosis/necrosis, but
not to the extent of cells cultured in UM containing sera of
HD patients. These findings suggest that both uremia and the
process of HD may impart a greater inhibitory effect on
MoDC function and survival in vitro compared to uremia
alone. Similar to HD patients, the sera of CAPD and CRF
patients have detectable levels of IL-12p70, which may
account for the enhanced production of IL-12p70 by MoDC
cultured in the presence of UM but not when cultured in
CM. However, the recruitment of more CAPD and CRF
patients may help to confirm these findings.
A previous study has shown that monocytes isolated from
HD patients exhibited low level expression of CD86 (B7.2)
following LPS stimulation, leading to impaired effector
activation of T cells in these patients.35 This study confirms
these conclusions and demonstrates that uremic monocytes
isolated from HD patients cultured in autologous UM, and
to a lesser extent when cultured in CM, have reduced ability
for endocytosis, reduced expression of costimulatory mole-
cules, and allo-stimulatory capacity following LPS stimula-
tion. However, uremic monocytes were capable of
differentiating into MoDC with appropriate cytokines but
this was impaired in the presence of autologous uremic
serum. Similarly, uremic MoDC generated in the presence of
autologous UM or CM displayed reduced capacity for
endocytosis and maturation following LPS stimulation.
However, uremic MoDC cultured in autologous UM, but
not when cultured in CM, exhibited enhanced production of
IL-12p70 and allogeneic T-cell proliferation (similar to UM-
cultured normal MoDC). This finding is likely to be
dependent on the presence of IL-12 in uremic serum
that may enhance the capacity of uremic MoDC to produce
IL-12p70 resulting in superior T-cell activation and
proliferation. The absence of any significant improvement
in uremic monocytes and MoDC functions when cultured in
CM compared to autologous UM suggests the likelihood of
an underlying intrinsic defect of uremic monocytes and
hence MoDC functions ex vivo, which was amplified in the
presence of UM.
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In this study, the observed functional impairments
in monocytes and MoDC in the presence of uremic serum
in vitro may contribute in part to the widespread immune
dysfunction reported in HD patients, including a higher
incidence of infections and malignancies, and displayed a
suboptimal response to vaccinations. A logical next step is to
determine whether improving uremic toxin clearance by
utilizing a more efficient dialyzer or using a different dialysis
modality (e.g. peritoneal dialysis, conventional thrice-weekly
HD, and daily or nocturnal dialysis) in HD-dependent CRF
patients improves DC functions. Prospective studies in
selected HD patients are currently ongoing in our laboratory
to address this issue. This may then enable nephrologists to
determine whether specific dialysis regimen could be
considered in selected HD patients with demonstrated severe
immune impairment (i.e. poor or non-responders to
hepatitis B vaccination) to improve their generalized
immunodeficiency.
MATERIALS AND METHODS
Thirteen HD-dependent CRF patients, 13 healthy controls, 3 CAPD-
dependent CRF patients and 3 CRF not maintained on dialysis were
enrolled in this study. This study was approved by the Local
Institutional Ethics Committee at The Queen Elizabeth Hospital and
informed consent was obtained before inclusion.
All patients were prospectively recruited from outpatient clinics,
in-center, and satellite dialysis units and had no clinically relevant
infections in the preceding 3 months. HD patients were maintained
on intermittent thrice-weekly HD using polysulfone membrane
(Fresenius Medical Care AG, Bad Homburg, Germany) achieving
Kt/v41.5. All patients had native or graft arterio-venous fistulas.
All CAPD patients had Kt/v 41.6. The mean7s.d. calculated
glomerular filtration rate (using Cockcroft Gault formula)36 of the
CRF patients not on dialysis was 24.378.1 ml/min. Most patients
were taking vitamin D supplements and/or aspirin (drugs known to
suppress normal DC functions37).
All patients were older than healthy controls (65.8711.2 and
43.572.4 years old; Mann–Whitney U-test, Po0.05). Peripheral
blood monocyte count of HD, CAPD, and CRF patients in this study
was 0.270.1 109/l, 0.2370.1 109/l, and 0.370.2 109/l (nor-
mal laboratory range 0.20–0.80 109/l) and was comparable to
healthy control (0.370.1 109/l; P¼NS). Urea concentrations in
all patients were consistently less than 40 mmol/l (range
18.7–28.5 mmol/l).
Ten milliliters of peripheral venous blood were obtained from
HD (pre-dialysis), CAPD, CRF patients, and healthy controls. Blood
was collected in heparinised tubes (BD Biosciences, San Diego, CA,
USA) and immediately centrifuged at 100 g for 10 min to separate
serum from cells. IL-12p70 levels were determined in the sera of HD
patients and healthy controls using an ELISA kit. Remaining sera
collected were heat-inactivated for 30 min in a 561C water bath to
deactivate endogenous complements and were stored frozen at
701C until use.
Reagents
FITC-, phycoerythrin-, and cychrome-conjugated mouse antihuman
monoclonal antibodies used to detect cell-surface markers human
leukocyte antigen-DR (clone G46-6), CD14 (clone MY4-FITC),
CD40 (clone mAb89), CD80 (clone L307.4), CD83 (clone HB15A),
CD86 (clone FUN1), CD95 (clone DX2), and CD206 (clone 19.2)
were used. The isotype-negative controls include IgG2b isotype
control (clone 27–35) and IgG2a isotype control (clone G155-178).
All antibodies were obtained from BD Biosciences, except for CD14
(Beckman Coulter, Hialeah, FL, USA), and CD40 and CD83 from
Immunotech (Marseille, Cedex, France). FITC-dextran, trypan blue,
and bacterial LPS were purchased from Sigma-Aldrich (St Louis,
MO, USA). Urea was purchased from Bio-Rad Laboratories
(Hercules, CA, USA) and urea solution was prepared from the
dilution of urea in distilled water. Monocytes and T cells were
isolated using CD14 and CD3 microbeads, respectively (Miltenyi
Biotec, Bergisch Gladbach, Germany).38 Cell-surface expression of
annexin V and propidium iodide was detected by using a
commercial kit (Bender MedSystems, Vienna, Austria). Levels of
IL-12p70 (BD Biosciences) were determined by an ELISA kit.
Tritiated thymidine was purchased from Amersham Biosciences
(Brown Deer, WI, USA). Solutions used include Ficoll-Hypaque
purchased from Amersham Biosciences, phosphate-buffered saline
from Sigma-Aldrich, and fluorescence-activated cell sorting lysing
solution from BD Biosciences. Fetal calf serum was obtained from
JRH Biosciences (Lenexa, Kansas, USA), rabbit serum from ICN
Pharmaceuticals (Costa Mesa, CA, USA), and human AB serum
from Australia Red Cross Service (South Australia, Australia).
Staining buffer contained phosphate-buffered saline with 1% v/v
fetal calf serum and 0.1% w/v sodium azide (Sigma-Aldrich). RPMI-
1640 (Sigma-Aldrich) was supplemented with 10% v/v human AB
or uremic serum (ABO-compatible with cultured cells), 2 mM
L-glutamine (MultiCel Trace Scientific, Victoria, Australia), sodium
pyruvate (ICN Pharmaceuticals), penicillin streptomycin (MultiCel
Trace Scientific), and sodium bicarbonate (Amresco), and referred
to as complete medium (CM) or uremic medium (UM),
respectively. IL-4 and granulocyte macrophage colony-stimulating
factor were purchased from Pepro Tech (Rocky Hill, NJ, USA) and
Sandoz Australia (North Ryde, NSW, Australia), respectively.
Isolation of normal monocytes and MoDC from healthy blood
donors
Peripheral blood mononuclear cells were isolated from buffy coat of
healthy blood donors (Australian Red Cross Blood Service) by
Ficoll-Hypaque density gradient separation and are referred to as
normal cells henceforth. Monocytes were isolated from peripheral
blood mononuclear cells using anti-CD14 microbeads using an
immunomagnetic bead separation technique with purity of 498%.
In brief, peripheral blood mononuclear cells were labeled with an
appropriate volume of anti-CD14 microbeads and were positively
selected using an automated magnetic cell separator (Automacss;
Miltenyi Biotec). Monocytes (1 106 cells/ml) were cultured for
24 h in medium, with LPS (10 ng/ml) added to induce maturation.
To obtain MoDC, monocytes (1 106 cells/ml) were cultured in
medium supplemented with 400 units/ml IL-4 and 800 units/ml
granulocyte macrophage colony-stimulating factor and were then
incubated in a humidified 371C CO2 incubator for 7 days to allow
differentiation of monocytes into MoDC.39 LPS (10 ng/ml) was
added in the final 48 h of incubation to induce MoDC maturation.
Monocytes were cultured in either CM or UM in parallel under
identical conditions to allow for direct comparisons of results.
Functional analysis of normal monocytes and MoDC cultured
in CM and UM
Detection of cell-surface molecules by flow cytometric analysis. LPS-
stimulated normal monocytes and MoDC were resuspended in
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staining buffer adjusted to a cell density of 1 106 cells/ml of buffer.
Cells were incubated for 20 min with 10% v/v rabbit serum and were
then aliquoted (1 105 cells) into polystyrene tubes (BD Bios-
ciences) and stained with human leukocyte antigen-DR, CD40,
CD80, CD83 (only for MoDC), CD86, CD95 (stains for Fas ligand),
and CD206 (macrophage mannose receptor) monoclonal anti-
bodies. Red cells were lysed with fluorescence-activated cell sorting
lysing solution, and washed twice in staining buffer. Two-color flow
cytometric analysis of 1 104 cells was performed by FACScans
flow cytometer with CellQuest software (BD Immunocytometry
Systems, San Jose, CA, USA).
Macrophage mannose receptor-dependent endocytosis deter-
mined by FITC-dextran uptake. In brief, 1 106 immature MoDC
were incubated in CM supplemented with 1 mg/ml FITC-dextran
for 60 min in a 371C incubator or on ice (negative control). Cells
were then washed and the uptake of FITC-dextran determined by
flow cytometric analysis.
Quantification of IL-12p70 by ELISA. IL-12p70 were deter-
mined in the sera (of HD patients and healthy controls), mediums,
and culture supernatants of LPS-stimulated monocytes and MoDC
by ELISA. In brief, 100 ml of undiluted serum and standards were
aliquoted into microplates precoated with anti-human IL-12p70
monoclonal antibody. Following incubation, the wells were washed
and 100 ml of diluted biotinylated anti-human IL-12p70 monoclonal
antibody were added. Following incubation and washes, 200 ml of
substrate solution were added. Reactions were stopped by adding
stop solution (1 M phosphoric acid). Optical densities of the wells
were determined using a microplate reader set to a wavelength of
450 nm. The level of detection was 7.8 pg/ml. IL-12p70 production
by monocytes and MoDC in the culture supernatants is the amount
of IL-12p70 detected by ELISA of culture supernatant less the
background level in culture mediums (i.e. amount present in CM
and UM).
Detection of apoptotic and necrotic cells. Apoptotic and
necrotic MoDC were identified by surface expression of annexin V
and propidium iodide, respectively, using a commercial kit. In brief,
cells were washed with phosphate-buffered saline and resuspended
in binding buffer (containing 10 mM HEPES/NaOH, pH 7.4, 140 mM
NaCl, 2.5 mM CaCl2) adjusted to a cell density of 2–5 106 cells/ml
of buffer. Positive control cells were treated 30 cm under ultraviolet
light for 2 min (i.e. to render cells apoptotic) and other cells
aliquoted into polystyrene tubes and stained with appropriate
volumes of annexin V and/or propidium iodide. Two-color flow
cytometric analysis of 1 104 cells was performed within 1 h.
Allogeneic T-cell stimulatory capacity determined by MLR. To
investigate the allo-stimulatory capacity of monocytes and MoDC,
LPS-stimulated monocytes and MoDC were co-cultured with
allogeneic T cells for 5 days in a MLR. Allogeneic T cells were
isolated by CD3 isolation kit by Automacss achieving a purity of
495%. T cells were then added to reducing concentrations of
monocytes/MoDC in a 96-well round bottom plates (Techno Plastic
Products, Trasadingen, Switzerland) in triplicates starting at a 1:1
monocytes/MoDC:T-cells ratio. Cells were cultured in CM and
incubated in a humidified 371C incubator containing 5% CO2 for 5
days, with 1 mCi/well of tritiated thymidine added during the last
18 h of culture. The cells were harvested on a 96-well Tomtec
harvester and tritiated thymidine incorporation measured in a
Microbeta Trilux liquid scintillation counter (EG&G Wallac, Turku,
Finland). Results were expressed as number of tritiated thymidine
incorporated cells.
Effects of urea on normal MoDC functions
To determine the effect of small MW uremic toxin on DC functions,
graded concentrations of urea solution (5, 20, and 40 mmol/l) was
added to CM containing normal monocytes. The functions of
normal monocytes and MoDC cultured in the presence of urea were
examined and compared with cells (from the same blood donor)
cultured in CM in parallel.
Effects of uremic sera of CAPD and CRF patients on MoDC
To determine whether the effect of uremic sera of HD patients on
MoDC function was a manifestation of the uremic state or the
process of HD, normal MoDC cultured in UM containing sera of
CRF not on dialysis and those maintained on CAPD were examined.
Isolation and functional analysis of uremic monocytes and
MoDC from HD patients
Six of the thirteen HD patients with hemoglobin of 4120 g/l
consented to having an additional 20 ml of peripheral blood
venesected. Blood was obtained from these patients immediately
pre-HD, thus avoiding any potential effects of HD on DC. The
functional characteristics of uremic monocytes (n¼ 3) and MoDC
(n¼ 3) derived from HD patients were determined following their
culture in either CM or autologous UM as described.
Statistical analysis
All experiments were performed at least in triplicate to ensure
reproducibility. Results were expressed as mean7s.d. Where
appropriate, Mann–Whitney U-test and Welch-corrected Student’s
t-test (for 2 groups of data) or non-parametric Kruskal–Wallis
analysis of variance test (for three or more groups of data) were used
to compare results, with Po0.05 deemed statistically significant and
PX0.05 as not statistically significant (NS). Representative histograms
were shown for experiments involving flow cytometric analysis and
mean7s.d. of MFI (difference between cell-surface expression and
isotype/negative control) shown. In addition, numerical tables
comparing MFI of costimulatory molecules and percentage of
apoptotic/necrotic cells of relevant experiments have been added for
clarity (Tables 1–4). Statistics were performed using GraphPad Instat
version 3.00 (GraphPad Software, San Diego, CA, USA).
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SUPPLEMENTARY MATERIAL
Figure S1. Uremic medium (sera of HD patients) inhibits the
expression of costimulatory molecule on uremic monocytes.
Figure S2. Uremic medium inhibits the allo-stimulatory capacity
of uremic monocytes.
Figure S3. Uremic medium (sera of CAPD and CRF patients) impairs
costimulatory molecule expression on MoDC.
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